Centre for Cancer Research and Cell Biology, Queen's University, Belfast, N. Ireland.
Hematology Am Soc Hematol Educ Program. 2009:629-35. doi: 10.1182/asheducation-2009.1.629.
Erythrocytosis results when there is an increased red cell mass and thus an increased hemoglobin. The causes can be divided into primary intrinsic defects of the erythroid progenitor cell and secondary defects, where factors external to the erythroid compartment are responsible. Both can then be further divided into congenital and acquired categories. Congenital causes include mutations of the erythropoietin receptor and defects of the oxygen-sensing pathway including VHL, PHD2 and HIF2A mutations. When fully investigated there remain a number of patients in whom no cause can be elucidated who are currently described as having idiopathic erythrocytosis. Investigation should start with a full history and examination. Having eliminated the common entity polycythemia vera, further direction for investigation is guided by the erythropoietin level. Clinical consequences of the various erythrocytoses are not clear, but in some groups thromboembolic events have been described in young patients. Evidence is lacking to define best management, but aspirin and venesection to a target hematocrit should be considered.
红细胞增多症是由于红细胞数量增加,从而血红蛋白增加所致。其原因可分为红系祖细胞的原发性内在缺陷和继发性缺陷,后者与红细胞以外的因素有关。两者都可以进一步分为先天性和后天性。先天性原因包括促红细胞生成素受体的突变和氧感应通路的缺陷,包括 VHL、PHD2 和 HIF2A 突变。经过充分调查,仍有一些患者的病因尚未明确,目前被描述为特发性红细胞增多症。调查应从完整的病史和检查开始。排除常见的真性红细胞增多症后,进一步的调查方向取决于促红细胞生成素的水平。各种红细胞增多症的临床后果尚不清楚,但在一些患者群体中,年轻患者已经出现了血栓栓塞事件。缺乏证据来确定最佳治疗方法,但应考虑阿司匹林和放血治疗以达到目标血细胞比容。